Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186324 · ClinicalTrials.gov registry record
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
A clinical trial, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- 23
- Enrollment target
NCT05186324 is a clinical trial that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 23 participants.
The verdict
NCT05186324 has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Pegunigalsidase alfa (PRX-102) is a long-term enzyme replacement therapy design for the treatment of patients with Fabry disease. Although in the clinical development program patient-reported outcomes and clinician-reported outcomes have been included, this may not allow for a sufficiently accurate assessment of the quality of life in patients with Fabry Disease treated with pegunigalsidase alfa. This study will collect the patient experience on the pegunigalsidase alfa treatment administered intravenously every 4 weeks in the BRIGHT-F51 clinical study (NCT03614234).
Interventions
- OTHER Interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2022-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05186324
The ClinicalTrials.gov registry entry for NCT05186324 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interview is the first listed.
NCT05186324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05186324 about?
NCT05186324 is a clinical study titled "Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion". Pegunigalsidase alfa (PRX-102) is a long-term enzyme replacement therapy design for the treatment of patients with Fabry disease. Although in the clinical development program patient-reported outcomes and clinician-reported outcomes have been included, this may not allow for a sufficiently accurate ...
What is the current status of trial NCT05186324?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2022-01-26. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05186324?
The interventions under investigation include: Interview (OTHER).
Who is sponsoring clinical trial NCT05186324?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.